Tightly Spring Now., page-31

Two separate developments:

Stephen Davis, CEO of Acadia Pharmaceuticals, disclosed yesterday the sale of US$6 million worth of ACAD shares after exercising options due to expire in March 2026.

https://www.streetinsider.com/SEC F... Oct 09 Filed by: DAVIS STEPHEN/16005210.html


Results from Newron’s Ph2/3 trial of sarizotan in the treatment of apneas in Rett syndrome are due to be released some time this quarter. Newron hopes that these study results will support marketing approval of sarizotan. In recent communications Newron has suggested that sarizotan might be of benefit for between 70 and 90% of Rett patients.

In a study published this month in The Journal of Molecular and Cellular Biology, scientists (not from Newron) note that in up to ~40% of Rett patients, there is prolongation of the cardiac QTc interval. They note that QTc prolongation calls for cautious use of drugs with a propensity to inhibit hERG channels. The finding of their study is that sarizotan produces potent hERG channel inhibition, which they claim is of critical importance for the use of sarizotan in the Rett patient population.

In conclusion, the authors note that are no approved therapies for Rett syndrome but that if sarizotan is found to be beneficial for apneas in Rett patients, use of the drug should only commence under clinical supervision with close monitoring of ECG and electrolyte levels. They advise that further caution should be taken to use the lowest effective dose, to avoid use in patients with existing LQTS or in combination with other QTc prolonging medications and that other risk factors for acquired LQTS also be considered.

https://www.newron.com/downloads/reports-presentations--webcasts/2019

https://www.sciencedirect.com/science/article/pii/S0022282819301531